• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

建立高效液相色谱-紫外检测法分析复方抗高血压制剂及人血浆中药物浓度。

Development of an HPLC-UV Method for the Analysis of Drugs Used for Combined Hypertension Therapy in Pharmaceutical Preparations and Human Plasma.

机构信息

Department of Analytical Chemistry, Faculty of Pharmacy, Bezmialem Vakif University, Fatih, 34093 Istanbul, Turkey.

出版信息

J Anal Methods Chem. 2013;2013:179627. doi: 10.1155/2013/179627. Epub 2013 Mar 24.

DOI:10.1155/2013/179627
PMID:23634320
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3619551/
Abstract

A simple, rapid, and selective HPLC-UV method was developed for the determination of antihypertensive drug substances: amlodipine besilat (AML), olmesartan medoxomil (OLM), valsartan (VAL), and hydrochlorothiazide (HCT) in pharmaceuticals and plasma. These substances are mostly used as combinations. The combinations are found in various forms, especially in current pharmaceuticals as threesome components: OLM, AML, and HCT (combination I) and AML, VAL, and HCT (combination II). The separation was achieved by using an RP-CN column, and acetonitrile-methanol-10 mmol orthophosphoric acid pH 2.5 (7 : 13 : 80, v/v/v) was used as a mobile phase; the detector wavelength was set at 235 nm. The linear ranges were found as 0.1-18.5  μ g/mL, 0.4-25.6  μ g/mL, 0.3-15.5  μ g/mL, and 0.3-22  μ g/mL for AML, OLM, VAL, and HCT, respectively. In order to check the selectivity of the method for pharmaceutical preparations, forced degradation studies were carried out. According to the validation studies, the developed method was found to be reproducible and accurate as shown by RSD ≤6.1%, 5.7%, 6.9%, and 4.6% and relative mean error (RME) ≤10.6%, 5.8%, 6.5%, and 6.8% for AML, OLM, VAL, and HCT, respectively. Consequently, the method was applied to the analysis of tablets and plasma of the patients using drugs including those substances.

摘要

建立了一种简单、快速和选择性的 HPLC-UV 方法,用于测定抗高血压药物物质:氨氯地平贝那普利(AML)、奥美沙坦酯(OLM)、缬沙坦(VAL)和氢氯噻嗪(HCT)在药物和血浆中的含量。这些物质主要作为组合使用。这些组合有多种形式,特别是在当前的药物中,它们是三种成分的组合:OLM、AML 和 HCT(组合 I)和 AML、VAL 和 HCT(组合 II)。分离是通过使用 RP-CN 柱实现的,乙腈-甲醇-10mmol 正磷酸 pH 2.5(7:13:80,v/v/v)作为流动相;检测波长设定为 235nm。AML、OLM、VAL 和 HCT 的线性范围分别为 0.1-18.5μg/mL、0.4-25.6μg/mL、0.3-15.5μg/mL 和 0.3-22μg/mL。为了检查该方法对药物制剂的选择性,进行了强制降解研究。根据验证研究,发现所开发的方法具有重现性和准确性,RSD 分别为≤6.1%、5.7%、6.9%和 4.6%,相对平均误差(RME)分别为≤10.6%、5.8%、6.5%和 6.8%,用于 AML、OLM、VAL 和 HCT。因此,该方法应用于包括这些物质的药物的片剂和患者血浆的分析。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/515c/3619551/13b19045f380/JAMC2013-179627.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/515c/3619551/caea37b1f6ac/JAMC2013-179627.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/515c/3619551/93c172c6d2c5/JAMC2013-179627.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/515c/3619551/a54166729e68/JAMC2013-179627.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/515c/3619551/99933c4616d5/JAMC2013-179627.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/515c/3619551/13b19045f380/JAMC2013-179627.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/515c/3619551/caea37b1f6ac/JAMC2013-179627.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/515c/3619551/93c172c6d2c5/JAMC2013-179627.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/515c/3619551/a54166729e68/JAMC2013-179627.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/515c/3619551/99933c4616d5/JAMC2013-179627.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/515c/3619551/13b19045f380/JAMC2013-179627.005.jpg

相似文献

1
Development of an HPLC-UV Method for the Analysis of Drugs Used for Combined Hypertension Therapy in Pharmaceutical Preparations and Human Plasma.建立高效液相色谱-紫外检测法分析复方抗高血压制剂及人血浆中药物浓度。
J Anal Methods Chem. 2013;2013:179627. doi: 10.1155/2013/179627. Epub 2013 Mar 24.
2
Novel Pure Component Contribution Algorithm (PCCA) and UHPLC Methods for Separation and Quantification of Amlodipine, Valsartan, and Hydrochlorothiazide in Ternary Mixture.用于分离和定量三元混合物中氨氯地平、缬沙坦和氢氯噻嗪的新型纯组分贡献算法(PCCA)和超高效液相色谱法
J AOAC Int. 2017 May 1;100(3):692-699. doi: 10.5740/jaoacint.16-0195. Epub 2016 Dec 21.
3
Simple RP-HPLC method for determination of triple drug combination of valsartan, amlodipine and hydrochlorothiazide in human plasma.简单反相高效液相色谱法测定人血浆中缬沙坦、氨氯地平和氢氯噻嗪的三联药物组合。
Acta Pharm. 2012 Mar;62(1):45-58. doi: 10.2478/v10007-012-0004-3.
4
Development and validation of a stability-indicating UPLC method for the determination of olmesartan medoxomil, amlodipine and hydrochlorothiazide degradation impurities in their triple-combination dosage form using factorial design of experiments.采用实验设计法开发并验证了一种超高效液相色谱法,用于测定其复方制剂中奥美沙坦酯、氨氯地平和氢氯噻嗪降解杂质的稳定性。
Biomed Chromatogr. 2021 Nov;35(11):e5194. doi: 10.1002/bmc.5194. Epub 2021 Jun 28.
5
Real-world effectiveness of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in high-risk patients and other subgroups.氨氯地平/缬沙坦及氨氯地平/缬沙坦/氢氯噻嗪在高危患者及其他亚组中的真实世界有效性。
Vasc Health Risk Manag. 2015 Jan 21;11:71-8. doi: 10.2147/VHRM.S76599. eCollection 2015.
6
Determination of active ingredients in antihypertensive drugs using a novel green HPLC method approach.采用新型绿色高效液相色谱法测定抗高血压药物中的有效成分。
Chemosphere. 2022 Sep;303(Pt 1):135053. doi: 10.1016/j.chemosphere.2022.135053. Epub 2022 May 23.
7
Four chemometric spectrophotometric methods for simultaneous estimation of amlodipine besylate and olmesartan medoxomil in their combined dosage form.四种化学计量分光光度法同时测定氨氯地平贝那普利片和奥美沙坦酯的含量。
Spectrochim Acta A Mol Biomol Spectrosc. 2022 Feb 5;266:120455. doi: 10.1016/j.saa.2021.120455. Epub 2021 Sep 29.
8
Real-world clinical experience of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in hypertension: the EXCITE study.氨氯地平/缬沙坦及氨氯地平/缬沙坦/氢氯噻嗪治疗高血压的真实世界临床经验:EXCITE研究
Curr Med Res Opin. 2014 Oct;30(10):1937-45. doi: 10.1185/03007995.2014.942415. Epub 2014 Jul 17.
9
Efficacy and safety of triple antihypertensive therapy with the olmesartan/amlodipine/hydrochlorothiazide combination.奥美沙坦/氨氯地平/氢氯噻嗪三联降压治疗的疗效和安全性。
Clin Drug Investig. 2012 Oct 1;32(10):649-64. doi: 10.1007/BF03261919.
10
Antihypertensive efficacy of olmesartan medoxomil or valsartan in combination with amlodipine: a review of factorial-design studies.奥美沙坦酯或缬沙坦联合氨氯地平的降压疗效:析因设计研究综述
Curr Med Res Opin. 2009 Jan;25(1):177-85. doi: 10.1185/03007990802597456.

引用本文的文献

1
Investigation of hydrolysis of olmesartan medoxomil in different pH buffers by simultaneously measuring olmesartan medoxomil and olmesartan.通过同时测定奥美沙坦酯和奥美沙坦来研究奥美沙坦酯在不同pH缓冲液中的水解情况。
PLoS One. 2025 May 2;20(5):e0321142. doi: 10.1371/journal.pone.0321142. eCollection 2025.
2
Application of an LC-MS/MS method for the analysis of amlodipine, valsartan and hydrochlorothiazide in polypill for a bioequivalence study.应用液相色谱-串联质谱法分析复方制剂中氨氯地平、缬沙坦和氢氯噻嗪用于生物等效性研究。
J Pharm Anal. 2017 Oct;7(5):309-316. doi: 10.1016/j.jpha.2017.06.001. Epub 2017 Jun 4.
3

本文引用的文献

1
Simultaneous determination of captopril and hydrochlorothiazide by time-resolved chemiluminescence with artificial neural network calibration.基于人工神经网络校准的时间分辨化学发光法同时测定卡托普利和氢氯噻嗪
J Pharm Anal. 2011 Feb;1(1):32-38. doi: 10.1016/S2095-1779(11)70006-5. Epub 2012 Jan 30.
2
Efficacy of Sevikar® compared to the combination of perindopril plus amlodipine on central arterial blood pressure in patients with moderate-to-severe hypertension: Rationale and design of the SEVITENSION study.西伐卡®对比培哚普利氨氯地平复方制剂对中重度高血压患者中心动脉血压疗效的研究:SEVITENSION 研究的原理和设计。
Contemp Clin Trials. 2011 Sep;32(5):710-6. doi: 10.1016/j.cct.2011.04.011. Epub 2011 May 14.
3
Development and Validation of a LC-MS/MS Method for the Simultaneous Estimation of Amlodipine and Valsartan in Human Plasma: Application to a Bioequivalence Study.
人血浆中氨氯地平和缬沙坦同时测定的液相色谱-串联质谱法的建立与验证:在生物等效性研究中的应用
Sci Pharm. 2014 Mar 26;82(3):585-600. doi: 10.3797/scipharm.1402-11. Print 2014 Jul-Sep.
Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: The TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study.
在高血压成年患者中使用奥美沙坦酯、苯磺酸氨氯地平与氢氯噻嗪三联治疗的多中心、随机、双盲、12 周、平行分组研究(TRINITY)。
Clin Ther. 2010 Jul;32(7):1252-69. doi: 10.1016/j.clinthera.2010.07.008.
4
Amlodipine/valsartan/hydrochlorothiazide triple combination therapy in moderate/severe hypertension: Secondary analyses evaluating efficacy and safety.氨氯地平/缬沙坦/氢氯噻嗪三联疗法治疗中重度高血压:评估疗效和安全性的二次分析。
Adv Ther. 2009 Nov;26(11):1012-23. doi: 10.1007/s12325-009-0077-7. Epub 2009 Dec 18.
5
Development and validation of a highly sensitive and robust LC-ESI-MS/MS method for simultaneous quantitation of simvastatin acid, amlodipine and valsartan in human plasma: application to a clinical pharmacokinetic study.一种用于同时定量人血浆中辛伐他汀酸、氨氯地平和缬沙坦的高灵敏度且稳健的液相色谱-电喷雾串联质谱法的开发与验证:应用于一项临床药代动力学研究
Biomed Chromatogr. 2009 Jun;23(6):615-22. doi: 10.1002/bmc.1161.
6
Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.贝那普利联合氨氯地平或氢氯噻嗪用于高危患者高血压的治疗
N Engl J Med. 2008 Dec 4;359(23):2417-28. doi: 10.1056/NEJMoa0806182.
7
Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the ACCOMPLISH study.高血压强化与固定复方治疗的血压反应预测因素:ACCOMPLISH研究
Blood Press. 2008;17(1):7-17. doi: 10.1080/08037050801972857.
8
Exceptional early blood pressure control rates: the ACCOMPLISH trial.卓越的早期血压控制率:ACCOMPLISH试验
Blood Press. 2007;16(2):80-6. doi: 10.1080/08037050701395571.
9
Quantitative determination of olmesartan in human plasma and urine by liquid chromatography coupled to tandem mass spectrometry.液相色谱-串联质谱法对人血浆和尿液中奥美沙坦进行定量测定。
J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Sep 1;856(1-2):190-7. doi: 10.1016/j.jchromb.2007.05.049. Epub 2007 Jun 16.
10
A rapid and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the estimation of amlodipine in human plasma.一种用于测定人血浆中氨氯地平的快速灵敏的液相色谱-串联质谱(LC-MS/MS)方法。
Biomed Chromatogr. 2007 Feb;21(2):169-75. doi: 10.1002/bmc.730.